Xenetic Biosciences Stock Price - XBIO

1.015
0.0108 (1.08%)
Upgrade to Real-Time
Regular Market
1.015
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Xenetic Biosciences Inc XBIO NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.0108 1.08% 1.015 0.99 1.02 1.02 1.0042 10:08:29
Bid Price Ask Price Spread Spread % News
0.9924 1.02 0.0276 2.71% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
41 9,372 $ 1.01 $ 9,491 270,950 0.44 - 15.25
Last Trade Time Type Quantity Stock Price Currency
10:10:57 25 $ 0.9924 USD

Xenetic Biosciences Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 6.38M 6.28M 5.88M $ 17.07k $ - -9.62 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 1.00 12.20%

more financials information »

Xenetic Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical XBIO Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.051.120.981.02153,346-0.035-3.33%
1 Month0.861.300.811.00359,2270.15518.02%
3 Months0.87831.300.440.8837279235,3400.136715.56%
6 Months1.241.880.441.26404,686-0.225-18.15%
1 Year0.7015.250.441.63448,2920.31545.0%
3 Years3.1415.250.442.52243,597-2.13-67.68%
5 Years0.2015.250.182.42165,5240.815407.5%

Xenetic Biosciences Description

Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.


Your Recent History
NASDAQ
XBIO
Xenetic Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.